Oslo - Delayed Quote NOK

Zelluna ASA (ZLNA.OL)

17.20 0.00 (0.00%)

At close: November 2 at 4:25:17 PM GMT+1

Zelluna ASA: Second Quarter 2026 results

GlobeNewswire 2mo ago

ZLNA.OL
0.00%
Zelluna receives Independent Data Monitoring Committee recommendation to continue patient enrolment in ZIMA-101

GlobeNewswire 2mo ago

ZLNA.OL
0.00%
Zelluna ASA: Notice of EGM – experienced international biotech executive proposed for election to the Board and Board member steps down

GlobeNewswire 2mo ago

ZLNA.OL
0.00%
BINV.ST
Zelluna doses first solid tumour patient with ZI-MA4-1 in the ZIMA-101 Phase 1 trial

GlobeNewswire 3mo ago

ZLNA.OL
0.00%
Zelluna ASA awarded NOK 16 million Research Council of Norway grant

GlobeNewswire 4mo ago

ZLNA.OL
0.00%
Zelluna ASA: Mandatory notification of trade – Return of lent shares following Private Placement

GlobeNewswire 4mo ago

ZLNA.OL
0.00%
ZLA
Zelluna ASA activates The Royal Marsden as second clinical site for ZIMA-101, expanding clinical execution capabilities

GlobeNewswire 4mo ago

ZLNA.OL
0.00%
ZLA
Zelluna ASA – Mandatory notification of trade – Subscription and share lending in Private Placement

GlobeNewswire 4mo ago

ZLNA.OL
0.00%
Zelluna ASA: Private Placement and Retail Offering successfully placed

GlobeNewswire 4mo ago

ZLNA.OL
0.00%
Zelluna ASA: Contemplated Private Placement and Retail Offering to Strengthen its Position Ahead of Initial Clinical Data

GlobeNewswire 4mo ago

ZLNA.OL
0.00%
ZLA
Zelluna ASA – Mandatory notification of trade

GlobeNewswire 7mo ago

ZLNA.OL
0.00%
Zelluna to host Capital Markets Update 2026

GlobeNewswire 7mo ago

ZLNA.OL
0.00%

U.S. markets closed

Zelluna ASA (ZLNA.OL)

Zelluna ASA: Second Quarter 2026 results

Zelluna receives Independent Data Monitoring Committee recommendation to continue patient enrolment in ZIMA-101

Zelluna ASA: Notice of EGM – experienced international biotech executive proposed for election to the Board and Board member steps down

Zelluna doses first solid tumour patient with ZI-MA4-1 in the ZIMA-101 Phase 1 trial

Zelluna ASA awarded NOK 16 million Research Council of Norway grant

Zelluna ASA: Mandatory notification of trade – Return of lent shares following Private Placement

Zelluna ASA activates The Royal Marsden as second clinical site for ZIMA-101, expanding clinical execution capabilities

Zelluna ASA – Mandatory notification of trade – Subscription and share lending in Private Placement

Zelluna ASA: Private Placement and Retail Offering successfully placed

Zelluna ASA: Contemplated Private Placement and Retail Offering to Strengthen its Position Ahead of Initial Clinical Data

Zelluna ASA – Mandatory notification of trade

Zelluna to host Capital Markets Update 2026